Get the Stockscreener App
0.5004
2.76%
-0.0142
After Hours:
.50
-0.0004
-0.08%
Io Biotech Inc stock is traded at $0.5004, with a volume of 1.55M.
It is down -2.76% in the last 24 hours and down -72.20% over the past month.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$0.5146
Open:
$0.503
24h Volume:
1.55M
Relative Volume:
0.36
Market Cap:
$32.97M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.2319
EPS:
-2.1574
Net Cash Flow:
$-72.06M
1W Performance:
+40.64%
1M Performance:
-72.20%
6M Performance:
-39.87%
1Y Performance:
-56.49%
1-Day Range:
$0.47
$0.5146
1-Week Range:
$0.3625
$0.5495
52-Week Range:
$0.3234
$2.79
Io Biotech Inc Stock (IOBT) Company Profile
Name
Io Biotech Inc
Sector
Industry
Phone
(457) 070-2980
Address
OLE MAALOES VEH 3, COPENHAGEN
Compare IOBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.5004 | 33.90M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Io Biotech Inc Stock (IOBT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-30-25 | Downgrade | TD Cowen | Buy → Hold |
Io Biotech Inc Stock (IOBT) Latest News
Tick level data insight on IO Biotech Inc. volatilityEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
How IO Biotech Inc. stock reacts to global recession fearsEntry Point & Safe Capital Growth Trade Ideas - newser.com
Multi asset correlation models including IO Biotech Inc.Earnings Trend Report & Weekly Breakout Watchlists - newser.com
How sentiment analysis helps forecast IO Biotech Inc.Earnings Performance Report & Risk Managed Trade Strategies - newser.com
What does recent volatility data suggest for IO Biotech Inc.July 2025 Setups & Consistent Growth Equity Picks - newser.com
Analysts Set IO Biotech, Inc. (NASDAQ:IOBT) Price Target at $8.00 - Defense World
Layoff Tracker: CSL Vifor, Bolt Cut Staff - BioSpace
Applying chart zones and confluence areas to IO Biotech Inc.Portfolio Update Summary & Long-Term Safe Investment Plans - newser.com
IO Biotech (NASDAQ:IOBT) Downgraded to Equal Weight Rating by Morgan Stanley - Defense World
IO Biotech (IOBT) Downgraded to Hold by TD Cowen | IOBT Stock Ne - GuruFocus
IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says - MarketScreener
IO Biotech Feels The Heat As US FDA Dashes Cylembio Filing Hopes - insights.citeline.com
IO Biotech (NASDAQ:IOBT) Receives "Hold" Rating from TD Cowen - MarketBeat
TD Cowen Maintains IO Biotech(IOBT.US) With Hold Rating - 富途牛牛
TD Cowen Downgrades IO Biotech to Hold From Buy - MarketScreener
FDA Recommends Against IO Biotech’s Cylembio Application - The Globe and Mail
Morgan Stanley Downgrades IO Biotech to Equalweight From Overweight, Cuts Price Target to $0.39 From $4 - MarketScreener
IO Biotech (NASDAQ:IOBT) Downgraded by HC Wainwright to “Neutral” - Defense World
IO Biotech stock rating downgraded to Hold by TD Cowen on FDA setback - Investing.com Canada
IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine - NewsBreak: Local News & Alerts
IO Biotech stock downgraded to Neutral by H.C. Wainwright on trial delays - Investing.com Canada
IOBT Downgraded to Neutral by HC Wainwright & Co. | IOBT Stock News - GuruFocus
IO Biotech drops after FDA recommends another late-stage study for cancer vaccine - TradingView
IO Biotech stock plummets after FDA recommends against BLA submission By Investing.com - Investing.com Australia
IO Biotech stock plummets after FDA recommends against BLA submission - Investing.com India
IO Biotech Advised Against Filing Biologics License Application for Cylembio; Plans to Cut 50% of Workforce - MarketScreener
Nasdaq Jumps 150 Points; US Pending Home Sales Rise - Benzinga
FDA recommends against IO Biotech’s BLA for melanoma vaccine By Investing.com - Investing.com Canada
Io Biotech Announces Restructuring Plan, Plans Global Workforce Reduction of ~50% with One-Time Charges of $1?1.5 Million - MarketScreener
IO Biotech provides update following pre-BLA meeting with FDA - MarketScreener
IO Biotech Faces FDA Setback with Cylembio; Plans New Study and Workforce Restructuring - Quiver Quantitative
FDA Recommends Against Cancer Vaccine BLA: IO Biotech's Cylembio Faces Setback, 50% Staff Cut - Stock Titan
Io Biotech Inc Stock (IOBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Io Biotech Inc Stock (IOBT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ahmad Qasim Iftikhar | Chief Medical Officer |
Dec 23 '24 |
Buy |
0.85 |
31,350 |
26,553 |
31,350 |
| Zocca Mai-Britt | Chief Executive Officer |
Dec 23 '24 |
Buy |
0.81 |
12,500 |
10,120 |
49,891 |
| Sullivan Amy | Chief Financial Officer |
Dec 23 '24 |
Buy |
0.83 |
10,250 |
8,483 |
84,632 |
| Smith Devin Whittemore | General Counsel |
Dec 23 '24 |
Buy |
0.81 |
12,000 |
9,720 |
16,938 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):